The Shkreli Pill

In this episode, Martin discusses the principles he believes are essential for building long-term wealth through trading. He explains his approach to identifying high-probability opportunities, managing risk, sizing positions, and maintaining discipline, while emphasizing the importance of probability, patience, and continuous learning in developing a successful trading strategy.

In this episode, Martin discusses what he believes is Meta's primary business weakness and how it could affect the company's long-term outlook. He also revisits his bearish thesis on SanDisk, examines the cyclical nature of the memory semiconductor industry through Micron, and analyzes Nektar Therapeutics, sharing his perspective on each company's valuation, competitive position, and p...

In this episode, Martin explains the balance sheet metric he believes provides particularly valuable insight into a company's financial health and long-term prospects. He discusses how to interpret financial statements, evaluate capital allocation, and identify strengths and weaknesses in a business, sharing his perspective on why this measure plays an important role in fundamental stock analy...

In this episode, Martin discusses the reported liquidation of a $20 billion hedge fund and the market conditions that may have contributed to the event. He examines the impact of leverage, risk management, liquidity, and portfolio construction, sharing his perspective on how large investment firms can become vulnerable during periods of market stress and the lessons traders can draw from high-prof...

In this episode, Martin joins TBPN to discuss the liquidation of investor Leopold and the market events that led up to it. He examines the role of leverage, risk management, and position sizing, while explaining the importance of situational awareness when navigating volatile markets. The conversation also explores trading psychology, portfolio management, and the lessons investors can draw from h...

In this episode, Martin explains why he believes a particular investment presents a compelling opportunity and the reasoning behind that view. He also analyzes Kioxia and Microsoft, discussing their businesses, competitive positioning, valuation, and long-term prospects. The episode concludes with a lesson on property, plant, and equipment (PP&E), where he explains how to interpret these balan...

In this episode, Martin reacts to an FDA advisory committee meeting involving Capricor Therapeutics, sharing his perspective on the discussion, the evidence presented, and the committee's deliberations. He examines the clinical data, regulatory considerations, and potential implications for the company's development program and investment outlook.

In this episode, Martin explains his approach to position sizing and portfolio allocation, discussing the mathematical principles he believes can improve long-term investment performance. He explores risk management, probability, expected returns, and capital preservation, illustrating how trade size can influence overall portfolio outcomes while sharing his perspective on balancing conviction wit...

In this episode, Martin discusses his outlook for South Korea and the factors he believes could influence the country's market and technology sector. He also explains why he thinks investors often overestimate their edge, outlines his bullish thesis on SK Hynix, and revisits Capricor Therapeutics, sharing his perspective on the company's recent developments and investment outlook.

In this episode, Martin discusses whether the memory semiconductor industry may be approaching the peak of its current market cycle. He examines supply and demand trends, pricing dynamics, industry competition, and valuation across memory companies, explaining the factors he believes could determine whether the sector continues to strengthen or begins to weaken.

In this episode, Martin discusses why he has become more cautious on SanDisk and explains the factors shaping his outlook for the company. He also reviews Jazz Pharmaceuticals, examines Sun Pharmaceutical Industries and Samsung Biologics, and analyzes Kioxia, sharing his perspective on each company's business, competitive position, valuation, and potential opportunities and risks.

In this episode, Martin discusses recent developments involving Capricor Therapeutics and shares his perspective on the company's disclosures and outlook. He also revisits his bearish thesis on AMD, analyzes Tyra Biosciences, explains why he is constructive on Sarepta, and discusses TENX, examining each company's business, valuation, competitive position, and the factors he believes could...

In this archive lesson, Martin discusses investing and financial analysis, explaining key concepts related to evaluating businesses, interpreting market behavior, and making investment decisions. He shares his perspective on valuation, risk management, and portfolio strategy while answering questions and illustrating the reasoning behind his approach to investing.

In this archive clip, Martin debates an 18-year-old participant about the pharmaceutical price increase that brought him widespread public attention. The discussion explores the reasoning behind the pricing decision, differing views on drug pricing and healthcare economics, and the ethical and business arguments raised by both sides during the exchange.

In this episode, Martin discusses Capricor Therapeutics and shares his perspective on the company's patient data and related public statements. He examines the clinical results, trial design, and regulatory considerations, explaining the factors that shape his investment outlook and why he questions aspects of the company's interpretation of the data.

In this episode, Martin discusses the investing approach of Steve Cohen and the characteristics he believes contribute to long-term trading success. He also shares his perspective on managing drawdowns, controlling risk during periods of underperformance, and developing exit strategies for short positions, explaining the principles he believes are important for disciplined portfolio management.

In this episode, Martin discusses why he believes certain recent market declines should not necessarily be viewed as buying opportunities. He also shares his perspective on SpaceX, comments on HIMS and its peptide-related business, revisits his bearish thesis on Intel, and analyzes SanDisk and Vertex, examining each company's business, valuation, competitive position, and the factors he believ...

In this episode, Martin discusses why he believes Tesla may continue to face downside pressure and examines Oracle, explaining why he views the stock as potentially oversold. He also shares his perspective on SPRB, Broadcom, and Google, analyzing each company's business, valuation, competitive position, and the factors he believes could influence their future performance.

In this episode, Martin debates the science and use of peptides, discussing their potential applications, limitations, and the evidence supporting various claims. Throughout the conversation, he responds to opposing viewpoints, critiques common arguments, and explains the reasoning behind his perspective on peptide research, biomedical science, and related topics.

In this episode, Martin discusses his expectations for Google's upcoming performance and shares his outlook on the company's future prospects. He also analyzes Cerebras and Sionna (SION), examining their businesses, valuations, and potential growth opportunities. In addition, he discusses Quhuo (QH), outlining his concerns about the company and explaining the factors that shape his investm...

In this episode, Martin discusses Google's latest earnings results and shares his outlook for the company's future performance. He also examines ServiceNow, explaining why he believes it may represent a value opportunity, and revisits his bearish thesis on CAPR, outlining the factors that continue to support his short position.

In this episode, Martin discusses a quantitative investing approach that he uses to compare and rank investment opportunities. He also shares his perspective on Kimi K3, analyzes Sionna (SION), and reviews Biohaven and Cue, examining each company's business, valuation, competitive position, and the factors he believes could influence their investment outlook.

This compilation brings together Martin’s discussions on preparing for periods of heightened market volatility and uncertainty. Across a range of clips, he examines changing market conditions, portfolio positioning, risk management, and stock-specific investment ideas, while explaining the reasoning behind his outlook and the strategies he believes investors should consider when navigating rapidly...

In this episode, Martin discusses his expectations for the market heading into the new trading week and revisits his outlook on Micron, examining whether he still considers the stock an attractive investment. He also comments on the possibility of a buyout involving Abivax and analyzes Abbott (ABT) and Exelixis, discussing their businesses, valuations, and the factors he believes could influence t...

In this episode, Martin discusses his outlook on the memory semiconductor industry and explains why he believes investor attention may be shifting toward quantum computing. He also shares his perspective on CoreWeave and PayPal, and analyzes TenX, Ultragenyx, and Evotec, examining each company's business, valuation, and the factors he believes could influence their future performance.